Xilio Therapeutics

Historical price data

Xilio Therapeutics is pioneering a novel approach to cancer treatment by creating therapies that remain inactive in healthy tissue but are selectively activated within tumors. This tumor-selective activation is intended to unlock the full potential of potent immunotherapies, such as cytokines and checkpoint inhibitors, which have historically been limited by severe side effects. The company's lead programs, including XTX101 (anti-CTLA-4) and XTX202 (IL-2), are in clinical development for various solid tumors. Xilio's strategy focuses on building a pipeline of targeted oncology assets to address significant unmet medical needs.

Proprietary Tumor-Activated Immuno-Oncology (TAIO™) platform that uses protease-cleavable masks to keep potent anti-cancer therapies inactive systemically, activating them selectively within the tumor microenvironment.

2 drugs in pipeline

Total raised: $71M

Xilio competes with other companies developing tumor-activated therapies (e.g., CytomX Therapeutics) and next-generation cytokine therapies. Its differentiation lies in its integrated TAIO™ platform applied across multiple therapeutic modalities, aiming to achieve superior tumor-selective activation and a better therapeutic index than systemic agents or competing targeted approaches.